FDA's New Oncology Chief Pledges to Keep OCE's Reforms Going

Angelo de Claro, M.D., the new head of the FDA's Oncology Center of Excellence, used his first interview in the role to vow to 'continue the innovation' behind the center's legacy, laying out an agenda built around organizational strength and continued regulatory modernization.

The Food and Drug Administration's Oncology Center of Excellence has a new leader, and in his first interview in the role Angelo de Claro, M.D., set out an agenda that reads less like a break with the past than a promise to keep it running. De Claro said he intends to "continue the innovation" behind the OCE's legacy, and framed his early priorities around two things: organizational strength and continued regulatory modernization.

That is a narrow set of words, but for an industry in which nearly every large-cap drugmaker now carries an oncology franchise, they are the words that matter most. The OCE is the single office that touches cancer drug reviews across the FDA's divisions — small molecules, biologics and devices alike — and its leadership sets the tone for how fast, and on what evidence, cancer medicines reach patients.

Why the OCE job carries outsized weight for drug developers

The Oncology Center of Excellence was created to pull cancer review work out of its silos. Before it existed, a cancer therapy, its companion diagnostic and any associated device were assessed by separate centers with separate cultures and separate clocks. The OCE was designed to coordinate that work, and it became the home of several of the agency's most closely watched experiments in regulatory process.

Two of those experiments dominate how sponsors plan oncology programs. The first is accelerated approval, the pathway that lets a cancer drug reach market on a surrogate endpoint — a tumor response rate, say — provided confirmatory evidence follows. The second is Project Orbis, the framework under which the FDA reviews an oncology application concurrently with regulators in partner countries, so that a drug can clear several markets on something close to the same timeline rather than years apart.

Both are legacy items in the literal sense: they were built by the office de Claro now runs, and both have been the subject of continuing debate about how much evidence is enough and how quickly confirmatory trials must read out. When a new chief says he wants to "continue the innovation" behind that legacy, sponsors will read it as a signal that the machinery stays in place.

What 'organizational strength' is likely to mean in practice

Of the two priorities de Claro named, organizational strength is the less glamorous and probably the more consequential. Review timelines in oncology are a function of staffing as much as of policy. An office that is short of reviewers, or churning through them, does not miss its statutory dates in a dramatic way — it stops taking on the discretionary work that sponsors value most: the early scientific advice meetings, the pre-submission alignment on endpoints, the flexibility to take a rolling submission.

Putting organizational capacity at the top of a stated agenda suggests the incoming chief sees the OCE's throughput as the binding constraint. For companies with cancer assets moving toward filing, that focus is arguably more useful than any new pathway, because it governs whether the existing pathways actually function at speed.

De Claro laid out those priorities in an interview with Fierce Biotech, his first since taking the reins of the center.

Regulatory modernization is the phrase to watch

"Continued regulatory modernization" is the kind of phrase that can cover a great deal of ground. In oncology it has historically meant a handful of concrete things: designing dose-optimization work into trials earlier rather than carrying a maximum-tolerated dose into registration; accepting real-world evidence where randomized data is impractical; standardizing the data formats sponsors submit so reviews are less manual; and coordinating with foreign regulators so that a single dataset can serve multiple filings.

None of those were announced as new initiatives. But the choice to name modernization as a continuing priority, rather than to announce a reset, tells sponsors something about planning risk. A company designing a Phase 3 oncology trial today is making assumptions about what the agency will accept in three to five years. Continuity in the OCE's stated direction lowers the cost of those assumptions. A change of direction — a sudden tightening of what counts as an acceptable surrogate endpoint, for instance — would force expensive redesigns across dozens of programs at once.

The read-through for cancer pipelines and for the market

Oncology is where the bulk of the biopharma industry's late-stage spending sits, and where a disproportionate share of equity value is tied to binary regulatory events. A leadership change at the office that governs those events is not a trading catalyst on its own, and there is no evidence it was treated as one. But it is a structural input into how the sector is valued, because the discount investors apply to a pre-approval asset is partly a judgment about regulatory predictability.

The broader market closed higher on Friday, 11 September 2026, with the S&P 500 tracker (NYSEARCA: SPY) finishing at $764.29, up 0.85% from the prior close of $757.83. The Nasdaq 100 fund (NASDAQ: QQQ) ended at $714.88, up 0.87%, and the Dow 30 vehicle (NYSEARCA: DIA) closed at $525.79, a gain of 0.97%. Those are broad-tape moves that reflect macro positioning rather than anything happening at the FDA; the point is simply that nothing in the oncology news flow disturbed the session.

What to watch from here

Three things will show whether the stated continuity is real. The first is the pace of confirmatory-trial enforcement under accelerated approval — whether the OCE keeps pressing sponsors to complete post-marketing commitments on schedule, and what happens to products that do not. The second is the cadence of Project Orbis concurrent reviews, which is the cleanest available measure of whether the international coordination machinery is still being used at volume.

The third is hiring. If organizational strength is genuinely the top priority, it should show up in reviewer headcount and in the availability of sponsor meetings, and companies will notice that long before any policy document appears. For drug developers with cancer programs in the clinic, the practical question posed by this leadership change is not whether the rules will change. It is whether the office has the people to apply them at the speed the industry has come to expect.

Key facts

• New OCE director: Angelo de Claro, M.D.
• Stated priorities: Organizational strength and continued regulatory modernization
• S&P 500 (SPY) close: $764.29, +0.85%, as of 11 Sep 2026 20:00 GMT
• Nasdaq 100 (QQQ) close: $714.88, +0.87%, as of 11 Sep 2026 20:00 GMT

Frequently asked questions

Who is Angelo de Claro?

Angelo de Claro, M.D., is the new head of the U.S. Food and Drug Administration's Oncology Center of Excellence. He gave his first interview in the role, in which he vowed to continue the innovation behind the center's legacy and outlined an agenda centered on organizational strength and continued regulatory modernization.

What does the FDA's Oncology Center of Excellence do?

The Oncology Center of Excellence coordinates the FDA's review of cancer products across the agency's separate centers for drugs, biologics and devices. It was created so that a therapy, its companion diagnostic and related devices could be assessed in a coordinated way rather than in isolation, and it houses several of the agency's oncology-specific review programs.

What is accelerated approval in oncology?

Accelerated approval lets the FDA clear a cancer drug based on a surrogate endpoint, such as tumor response rate, that is reasonably likely to predict clinical benefit, rather than waiting for survival data. The sponsor is then required to run confirmatory trials. The pathway speeds access but has drawn continuing debate over evidence standards and follow-through.

What is Project Orbis?

Project Orbis is an FDA framework under which an oncology application is reviewed concurrently by the FDA and regulators in partner countries. The aim is to let a cancer drug reach several markets on roughly the same timeline instead of sequentially, reducing the lag patients outside the United States face after a U.S. approval.

Does this leadership change affect pending cancer drug approvals?

No specific pending application has been tied to the change. De Claro has signaled continuity rather than a reset, which reduces the risk that sponsors face sudden shifts in evidence requirements. The practical variable he identified is organizational capacity, since staffing governs review throughput and the availability of scientific advice meetings for sponsors.

How did the broader market close on the day of the interview?

As of the last trade on Friday, 11 September 2026, the S&P 500 tracker SPY closed at $764.29, up 0.85% from $757.83. The Nasdaq 100 fund QQQ closed at $714.88, up 0.87%, and the Dow 30 vehicle DIA finished at $525.79, up 0.97%. Those moves reflected broad market positioning, not oncology-specific news.

Sources

• In first interview as FDA oncology chief, Angelo de Claro vows to ‘continue the innovation’ behind OCE legacy — Fierce Biotech

Photo: Edward Jenner · Pexels Licence — source